Biotechnologijų centras - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 78,363 | 93,300 | 37,771 | 27,222 | 22,545 | 13,000 | 38,914 | 4,850 |
| Profit before tax | - | - | - | - | - | - | - | - |
| Net profit | 1,395 | -99,494 | -580,097 | -192,425 | -53,965 | 6,016 | 15,818 | -288 |
| Equity | -1,229,750 | -1,329,244 | -1,909,341 | -284,737 | -338,872 | -332,856 | -317,038 | -317,326 |
| Liabilities | 1,693,705 | 2,346,344 | 2,309,865 | 806,045 | 290,006 | 290,157 | 289,202 | 294,215 |
| Non-current assets | 463,277 | 990,816 | 411,276 | 528,744 | 434 | 2,270 | 1,369 | 468 |
| Current assets | 678 | 26,284 | -10,752 | -7,436 | -49,300 | -44,969 | -29,205 | -23,579 |
| Total assets | 463,955 | 1,017,100 | 400,524 | 521,308 | -48,866 | -42,699 | -27,836 | -23,111 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 3,257 | 939 | 21 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -96.8% | +19.1% | -59.5% | -27.9% | -17.2% | -42.3% | +199.3% | -87.5% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 0.3% | -9.8% | -144.8% | -36.9% | - | - | - | - |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | - | - | - | - | - | - | - |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 1.8% | -106.6% | -1535.8% | -706.9% | -239.4% | 46.3% | 40.6% | -5.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | - | - | - | - | - | - | - |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | - | - | - | - |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 78,363 | 93,300 | 37,771 | 21,778 | 12,883 | 13,000 | 38,914 | 4,850 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Biotechnologijų centras - Social security debts
The amount of overdue SODRA debt for the company Biotechnologijų centras as of the last working day is: 12 €
| From | To | Debt, € |
|---|---|---|
| 2026-09-05 | 2026-09-16 | 12.02 |
| 2026-08-26 | 2026-09-02 | 12.02 |
| 2026-08-23 | 2026-08-23 | 12.02 |
| 2026-08-19 | 2026-08-19 | 12.02 |
| 2026-08-16 | 2026-08-17 | 12.02 |
| 2026-07-26 | 2026-08-14 | 12.02 |
| 2026-07-23 | 2026-07-25 | 12.28 |
| 2026-07-19 | 2026-07-22 | 12.02 |
| 2026-06-11 | 2026-07-17 | 12.02 |
| 2026-05-17 | 2026-06-08 | 12.02 |
| 2026-05-03 | 2026-05-14 | 9.02 |
| 2026-04-27 | 2026-04-29 | 9.02 |
| 2026-04-26 | 2026-04-26 | 8.96 |
| 2026-04-24 | 2026-04-25 | 9.02 |
| 2026-04-20 | 2026-04-23 | 8.96 |
| 2026-03-29 | 2026-04-15 | 5.96 |
| 2026-03-17 | 2026-03-27 | 5.96 |
| 2026-03-15 | 2026-03-16 | 2.96 |
| 2026-02-18 | 2026-03-11 | 2.96 |
| 2024-03-18 | 2024-03-31 | 4.22 |
| 2024-02-19 | 2024-03-17 | 1.70 |
| 2022-12-16 | 2023-01-02 | 1.09 |
| 2022-11-21 | 2022-11-30 | 1.24 |
| 2022-11-17 | 2022-11-18 | 1.24 |
| 2022-10-28 | 2022-11-02 | 3.39 |
| 2022-09-16 | 2022-10-06 | 301.72 |
| 2022-08-31 | 2022-09-15 | 280.80 |
| 2022-08-23 | 2022-08-30 | 285.29 |
Biotechnologijų centras - VMI tax arrears
As of 2026-09-14, the amount of overdue STI tax debt of the company Biotechnologijų centras is: 2,573 €
| From | To | Overdue, € |
|---|---|---|
| 2026-03-27 | 2026-09-14 | 2572.51 |
| 2026-03-20 | 2026-03-26 | 3617.77 |
| 2026-01-01 | 2026-03-08 | 2572.51 |
| 2025-12-01 | 2025-12-31 | 2564.19 |
| 2025-11-02 | 2025-11-30 | 2544.99 |
| 2025-10-02 | 2025-11-01 | 2525.15 |
| 2025-09-01 | 2025-10-01 | 2505.95 |
| 2025-08-28 | 2025-08-31 | 2503.39 |
| 2025-08-01 | 2025-08-27 | 2486.11 |
| 2025-07-21 | 2025-07-31 | 2478.85 |
| 2025-07-01 | 2025-07-20 | 2465.65 |
| 2025-06-22 | 2025-06-30 | 2457.04 |
| 2025-06-19 | 2025-06-21 | 2478.26 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Biotechnologiju centras, UAB (code 301171103) is a Private Limited Liability Company engaged in research and experimental development on other natural sciences and engineering. In 2025, the company generated €4.8K in revenue and posted a net loss of €288, compared with net profit of €15.8K in 2024 and €6.0K in 2023. Revenue fell sharply from €38.9K in 2024 to €4.8K in 2025, after rising from €13.0K in 2023. Profitability weakened materially, and the 2025 margin turned negative at -5.9%. The balance sheet remained under pressure: equity was negative at -€317.3K, liabilities stood at €294.2K, and reported total assets were -€23.1K. Over the three-year period, the company moved from modest revenue growth and positive earnings to a much smaller operating scale and a slight loss in 2025. Revenue per employee was €4.8K, indicating very limited output per staff member. Return and turnover measures should be interpreted cautiously given the negative equity and asset base.